Decipher Identifies a Molecular Subtype Most Likely to Benefit from Neoadjuvant KEYTRUDA Immunotherapy in Bladder Cancer Patients

NCCN Guidelines Designate Decipher Prostate as “Recommended” for Men with Adverse Pathology after Radical Prostatectomy

Decipher Prostate RP Identifies Patients Likely to Benefit from Hormonal Therapy in Men with Recurrent Prostate Cancer

Decipher GRID Signature Predicts Benefit from Chemotherapy in Men Diagnosed with Metastatic Prostate Cancer

Decipher Biosciences Announces Addition of Dr. Robert S. Epstein as Chairman and Kathy Hibbs, Esq. to its Board of Directors

Decipher Biosciences Announces Publication of a Prospective Clinical Study Demonstrating that the Use of Decipher Prostate RP Guides Post-Operative Management Decisions and Improves Patient Outcomes

Decipher Biosciences Achieves Major Medicare Milestone for Decipher Prostate Genomic Tests

Decipher Biosciences Announces Research Collaboration with Dendreon to Identify Genomic Drivers of Patient Response to Sipuleucel-T